


A quick guide for patients

Mounjaro® (tirzepatide)

once weekly
mounjaro®
(tirzepatide) injection

Four things you should know about your Mounjaro KwikPen®

- Each KwikPen is equal to 4 once weekly injections of Mounjaro. You should record the date of each injection.
- Needles are not included in the pack, you will need to purchase KwikPen compatible needles separately.
- You should prime your KwikPen before each injection. Refer to the Instructions for Use (IFU) leaflet in the pack.
- There will be leftover liquid in the KwikPen after the 4th and final dose, **this is expected**. After 4 doses, you should throw away (discard) the KwikPen, including the leftover liquid.



Needles are required and should be purchased separately. Refer to the IFU for Information.



Proper use of KwikPen in accordance with the Mounjaro KwikPen IFU leaflet, including recording your doses, is important to allow Lilly to best assist you with future queries.

Speak to your doctor or pharmacist about which needle tips are suitable for you. Needle tips are not included with the Mounjaro multi-use KwikPen. Please refer to the Instructions for Use leaflet that was provided with your Mounjaro, and the "How to Inject" step-by-step video for your multi-use KwikPen, via the QR code provided in this leaflet.

Getting started on your once weekly Mounjaro*

* 1 multi-use KwikPen = 4 weeks of supply.


Your doctor will start you on Mounjaro 2.5 mg once weekly. They may increase your dose to 5 mg after 4 weeks, and individualise your dose further based on treatment goals.



Missed a dose?

If you miss or forget your dose, it should be taken as soon as you remember. If there are **fewer than 3 days** until your next dose is due, then skip the missed dose. Inject your next dose as usual on your regular day.

For example, if your regular dose day is Monday:





Scan the QR code to watch
the **"How to Inject"** step-by-step video
for your multi-use KwikPen

Managing side effects

As with all medicines, you may experience side effects with Mounjaro. The **most common** side effects with Mounjaro are **nausea, diarrhoea, constipation, vomiting and abdominal pain**. These side effects are usually only **mild to moderate** and **decrease over time** in most patients. They are most common when first starting Mounjaro or when the dose is increased.

Please refer to the Consumer Medicine Information (CMI) leaflet for a full list of side effects that may occur with Mounjaro. If you experience any side effects while on Mounjaro, please report them to your doctor.

Talking about your Mounjaro



Travelling

Tell your doctor, pharmacist, or diabetes nurse educator if you are planning to travel overseas.



Surgery

Let your doctor know if you plan to have any surgery or need general anaesthesia for any reason.

Storage and handling



Store Mounjaro between 2°C–8°C. Do not freeze or shake Mounjaro



If Mounjaro is dropped on a hard surface, do not use



Mounjaro multi-use KwikPen may be stored outside of a refrigerator at room temperature (below 30°C) for up to 30 days



Store Mounjaro in a safe space protected from light

Scan the QR code to visit the Mounjaro Website



About Mounjaro



Downloadable
Resources



Lifestyle Tips
& Habits



CMI=Consumer Medicine Information.

Reporting side effects and product complaints

Please review the Consumer Medicine Information (CMI) leaflet for your multi-use KwikPen before taking Mounjaro. You can access the CMI online at www.lilly.com.au/en/products.

Side effects and product complaints should be reported. If you are worried about a side effect while taking a Lilly medicine, please contact your doctor. To report a side effect or a product complaint about a Lilly medicine, please call Lilly on 1800 454 559.

For more information, please speak to your doctor

This leaflet does not replace the Consumer Medicine Information (CMI) leaflet that came with your Mounjaro. This information is brought to you by Lilly, the manufacturers of this medicine.

▼ This medicine is subject to additional monitoring in Australia due to approval of an extension of indications. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.



© 2025 Eli Lilly Australia Pty Limited. Mounjaro® and KwikPen® are registered trademarks of Eli Lilly and Company. Eli Lilly Australia Pty Limited. ABN 39 000 233 992. Level 9, 60 Margaret St, Sydney NSW 2000. Telephone: 1800 454 559. Date of preparation: March 2025. PP-TR-AU-0570. 2007656.